Definitive Healthcare (DH) Morgan Stanley 23rd Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley 23rd Annual Global Healthcare Conference summary
8 Jul, 2026Company overview and market positioning
Founded in 2011 to address gaps in mapping the healthcare ecosystem, evolving from reference data to holistic datasets including claims and affiliations.
Solutions now span diversified, life sciences, and medical device segments, with data products serving a broad customer base.
Differentiation centers on high data quality, granular mapping, and agnostic integration with customer systems.
Focus on delivering data through multiple channels, including UI/UX, APIs, and direct integrations.
Partnerships with platforms like Databricks and Snowflake enable efficient data movement and audience targeting.
Strategic priorities and operational changes
Four pillars guide strategy: data quality, integration, customer success, and innovation in digital activation and master data management.
Reoriented internal operations for clarity and predictability, improving communication with investors and employees.
Leadership refresh blended domain expertise with experienced executives to enhance execution.
Commission structures revised to align sales and retention, improving customer satisfaction and renewals.
Radical transparency and open communication fostered organizational buy-in and adaptability.
Financial outlook and capital allocation
Near-term focus on revenue stabilization and eventual return to growth, with confidence in expanding margins as growth resumes.
High incremental margins and strong cash generation underpin a robust business model.
Share buybacks prioritized over acquisitions due to market conditions and strategic alignment.
Board provides active support and guidance, emphasizing building a generational, long-term business.
Latest events from Definitive Healthcare
- Q2 2026 revenue fell 9% but profit exceeded guidance amid innovation and ongoing macro headwinds.DH
Q2 2026 - Q1 2026 met guidance with improved margins despite a $197.2M goodwill impairment charge.DH
Q1 2026 - Director elections, auditor ratification, equity plan increase, and say-on-pay up for vote.DH
Proxy filing - Annual meeting covers director elections, auditor ratification, equity plan amendment, and say-on-pay.DH
Proxy filing - Q4 and full year 2025 beat guidance, but goodwill impairments led to large net losses.DH
Q4 2025 - Q2 revenue and adjusted EBITDA rose, but a $363.6M goodwill impairment drove a large net loss.DH
Q2 2024 - Q3 revenue beat guidance, but net loss deepened on goodwill impairment; $100M buyback announced.DH
Q3 2024 - Q1 2025 revenue beat guidance, but a $176.5M goodwill impairment drove a net loss.DH
Q1 2025 - Unified platform and streamlined sales processes target growth by late 2025.DH
27th Annual Needham Growth Conference